The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Effect of Statins on Skeletal Muscle Function
Open accessAbstract
Background—: Many clinicians believe that statins cause muscle pain, but this has not been observed in clinical trials, and the effect of statins on muscle performance has not been carefully studied. Methods and Results—: The Effect of Statins on Skeletal Muscle Function and Performance (STOMP) study assessed symptoms and measured creatine kinase, exercise capacity, and muscle strength before and after atorvastatin 80 mg or placebo was administered for 6 months to 420 healthy, statin-naive subjects. No individual creatine kinase value exceeded 10 times normal, but average creatine kinase increased 20.8±141.1 U/L ( P <0.0001) with atorvastatin. There were no significant changes in several measures of muscle strength or exercise capacity with atorvastatin, but more atorvastatin than placebo subjects developed myalgia (19 versus 10; P =0.05). Myalgic subjects on atorvastatin or placebo had decreased muscle strength in 5 of 14 and 4 of 14 variables, respectively ( P =0.69). Conclusions—: These results indicate that high-dose atorvastatin for 6 months does not decrease average muscle strength or exercise performance in healthy, previously untreated subjects. Nevertheless, this blinded, controlled trial confirms the undocumented impression that statins increase muscle complaints. Atorvastatin also increased average creatine kinase, suggesting that statins produce mild muscle injury even among asymptomatic subjects. This increase in creatine kinase should prompt studies examining the effects of more prolonged, high-dose statin treatment on muscular performance. Clinical Trial Registration—: URL: http://www.clinicaltrials.gov . Unique identifier: NCT00609063.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Among the 420 statin-naïve subjects randomized to atorvastatin 80 mg daily or placebo for 6 months, 9.4% of the statin-treated and 4.6% of control subjects met the study definition of myalgia (P = 0.054)”
In the citing paper
“The STOMP study also found no differences in the measures of muscle strength or exercise performance between statin-treated and placebo subjects.”
In the citing paper
“The Effects of Statins on Muscle Performance (STOMP) study is, to our knowledge, the only randomized, double-blind, placebo-controlled study specifically designed to examine the effect of statins on skeletal muscle symptoms and performance.22”
In the citing paper
“suggesting that the incidence of muscle complaints due to the statin is considerably less than that reported in observational trials.”
In the citing paper
“Discomfort and weakness typically occur early (within 4–6 weeks after starting statin therapy22), but may still occur after many years of treatment.”
In the citing paper
“One study, designed specifically to study the effects of statins on muscle symptoms, suggests that the frequency of muscle-related complaints is ≏ 5%. 217”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [217]
In the citing paper
“Medications such as statins may provoke symptoms such as muscle pain or weakness, which can be confused with normal post-exercise soreness, especially in individuals not accustomed to PRT [[588], [589], [590]].”
From Global consensus on optimal exercise recommendations for enhancing healthy longevity in older adults (ICFSR) (2025) · cites this paper as [588]
In the citing paper
“Medications such as statins may provoke symptoms such as muscle pain or weakness, which can be confused with normal post-exercise soreness, especially in individuals not accustomed to PRT [[588], [589], [590]].”
From Global consensus on optimal exercise recommendations for enhancing healthy longevity in older adults (ICFSR) (2025) · cites this paper as [588]
In the citing paper
“One study, designed specifically to study the effects of statins on muscle symptoms, suggests that the frequency of muscle-related complaints is ~5%.217”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [217]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674
Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J. J., Gotto, A. M., Kastelein, J. J. P., Köenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2009) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000344393.60303.0a · Cited by 3,641
Arky, R. A. (1994) · Cited by 2,632
Thompson, P. D., Clarkson, P., & Karas, R. H. (2003) · JAMA · doi:10.1001/jama.289.13.1681 · Cited by 1,463
Self-citationBruckert, E., Hayem, G., Dejager, S., Yau, C., & Bégaud, B. (2005) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-005-5686-z · Cited by 1,226
ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins
Writing Committee Members:, Pasternak, R. C., Smith, S. C., Bairey-Merz, C. N., Grundy, S. M., Cleeman, J. I., & Lenfant, C. (2002) · Circulation · doi:10.1161/01.cir.0000032466.44170.44 · Cited by 1,088
Cerivastatin and Reports of Fatal Rhabdomyolysis
Staffa, J. A., Chang, J. T., & Green, L. (2002) · New England Journal of Medicine · doi:10.1056/nejm200202143460721 · Cited by 627
Statin-associated myopathy with normal creatine kinase levels
Phillips, P. S., Haas, R. H., Bannykh, S., Hathaway, S., Gray, N. L., Kimura, B. J., Vladutiu, G. D., England, J. D. F., & and the Scripps Mercy Clinical Research Center* (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-7-200210010-00009 · Cited by 565
Pasternak, R. C., Smith, S. C., Merz, C. N. B., Grundy, S. M., Cleeman, J. I., & Lenfant, C. J. M. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)02030-2 · Cited by 497
The muscle-specific ubiquitin ligase atrogin-1/MAFbx mediates statin-induced muscle toxicity
Hanai, J., Cao, P., Tanksale, P., Imamura, S., Koshimizu, E., Zhao, J., Kishi, S., Yamashita, M., Phillips, P. S., Sukhatme, V. P., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32741 · Cited by 281
Flagged first, then by citations
Cited by
Sorted by citations
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000625 · Cited by 6,185
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.003 · Cited by 2,691
Interpretation of the evidence for the efficacy and safety of statin therapy
Collins, R., Reith, C., Emberson, J., Armitage, J., Baigent, C., Blackwell, L., Blumenthal, R., Danesh, J., Smith, G. D., DeMets, D., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31357-5 · Cited by 1,857
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.002 · Cited by 1,751
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.08.018 · Cited by 1,582
Stroes, E. S., Thompson, P. D., Corsini, A., Vladutiu, G. D., Raal, F. J., Ray, K. K., Roden, M., Stein, E., Tokgözoğlu, L., Nordestgaard, B. G., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv043 · Cited by 1,443
Self-citationGrundy, S. M., Stone, N. J., Bailey, A. L., Beam, C. T., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S. D., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000624 · Cited by 933
Ward, N. C., Watts, G. F., & Eckel, R. H. (2019) · Circulation Research · doi:10.1161/circresaha.118.312782 · Cited by 799
Statin-Associated Side Effects
Thompson, P. D., Panza, G. A., Zaleski, A. L., & Taylor, B. A. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.02.071 · Cited by 776
Self-citationNewman, C. B., Preiss, D., Tobert, J. A., Jacobson, T. A., Page, R. L., II, Goldstein, L. B., Chin, C. C., Tannock, L. R., Miller, M. J., Raghuveer, G., et al. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atv.0000000000000073 · Cited by 790
ESC/EAS Guidelines for the management of dyslipidaemias
Catapano, A. L., Reiner, Ž., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.06.028 · Cited by 706
Kutner, J. S., Blatchford, P. J., Taylor, D. H., Ritchie, C. S., Bull, J. H., Fairclough, D. L., Hanson, L. C., LeBlanc, T. W., Samsa, G. P., Wolf, S., et al. (2015) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2015.0289 · Cited by 502
An assessment by the statin muscle safety task force: 2014 update
Rosenson, R. S., Baker, S. K., Jacobson, T. A., Kopecky, S. L., & Parker, B. A. (2014) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2014.03.004 · Cited by 485
Self-citationPrevalence of statin intolerance: a meta-analysis
Bytyçi, I., Penson, P. E., Mikhailidis, D. P., Wong, N. D., Hernandez, A. V., Sahebkar, A., Thompson, P. D., Mazidi, M., Rysz, J., Pella, D., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac015 · Cited by 481
Self-citationMoriarty, P. M., Thompson, P. D., Cannon, C. P., Guyton, J. R., Bergeron, J., Zieve, F. J., Bruckert, E., Jacobson, T. A., Kopecky, S. L., Baccara-Dinet, M. T., et al. (2015) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2015.08.006 · Cited by 470
Self-citationSafety and efficacy of statin therapy
Adhyaru, B. B., & Jacobson, T. A. (2018) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0098-5 · Cited by 424
Banach, M., Rizzo, M., Toth, P. P., Farnier, M., Davidson, M. H., Al‐Rasadi, K., Aronow, W. S., Athyros, V. G., Djuric, D. M., Владиславович, Е. М., et al. (2015) · Archives of Medical Science · doi:10.5114/aoms.2015.49807 · Cited by 386
Grundy, S. M. (2013) · Journal of clinical lipidology · doi:10.1016/j.jacl.2013.10.001 · Cited by 353
Gupta, A., Thompson, D., Whitehouse, A., Collier, T., Dahlof, B., Poulter, N., Collins, R., & Sever, P. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31075-9 · Cited by 343
Immune-mediated necrotizing myopathy: clinical features and pathogenesis
Allenbach, Y., Benvéniste, O., Stenzel, W., & Boyer, O. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-020-00515-9 · Cited by 342
Grundy, S. M., Arai, H., Barter, P. J., Bersot, T. P., Betteridge, D. J., Carmena, R., Cuevas, A. M., Davidson, M. H., Genest, J. J., Kesäniemi, Y. A., et al. (2013) · Journal of clinical lipidology · doi:10.1016/j.jacl.2013.12.005 · Cited by 334
Serban, M.-C., Colantonio, L. D., Manthripragada, A. D., Monda, K. L., Bittner, V. A., Banach, M., Chen, L., Huang, L., Dent, R., Kent, S. T., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.12.036 · Cited by 318
Izquierdo, M., de Souto Barreto, P., Arai, H., Bischoff-Ferrari, H. A., Cadore, E. L., Cesari, M., Chen, L.-K., Coen, P. M., Courneya, K. S., Duque, G., et al. (2025) · The Journal of nutrition, health and aging · doi:10.1016/j.jnha.2024.100401 · Cited by 273
Effects of statins on mitochondrial pathways
Mollazadeh, H., Tavana, E., Fanni, G., Bo, S., Banach, M., Pirro, M., von Haehling, S., Jamialahmadi, T., & Sahebkar, A. (2021) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.12654 · Cited by 270
A systematic review of statin-induced muscle problems in clinical trials
Ganga, H. V., Slim, H. B., & Thompson, P. D. (2014) · American Heart Journal · doi:10.1016/j.ahj.2014.03.019 · Cited by 253
Self-citationMancini, G. B. J., Baker, S. K., Bergeron, J., FITCHETT, D. H., Frohlich, J. J., Genest, J. J., Gupta, M., Hegele, R. A., Ng, D. S., Pearson, G. J., et al. (2016) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2016.01.003 · Cited by 257
2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia
Blumenthal, R. S., Morris, P. B., Gaudino, M., Johnson, H. M., Anderson, T. S., Bittner, V. A., Blankstein, R., Brewer, L. C., Cho, L., de Ferranti, S. D., et al. (2026) · JACC · doi:10.1016/j.jacc.2025.11.016 · Cited by 304
Statin-Induced Myopathy Is Associated with Mitochondrial Complex III Inhibition
Schirris, T. J. J., Renkema, G. H., Ritschel, T., Voermans, N. C., Bilos, A., van Engelen, B. G. M., Brandt, U., Koopman, W. J. H., Beyrath, J., Rodenburg, R. J., et al. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.08.002 · Cited by 235
Cai, T., Abel, L., Langford, O., Monaghan, G., Aronson, J. K., Stevens, R., Lay-Flurrie, S. L., Koshiaris, C., McManus, R. J., Hobbs, R. F., et al. (2021) · BMJ · doi:10.1136/bmj.n1537 · Cited by 237
A randomized trial of Coenzyme Q10 in patients with confirmed statin myopathy
Taylor, B. A., Lorson, L., White, C. M., & Thompson, P. D. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.12.016 · Cited by 200
Self-citationStatin-induced myalgia and myositis: an update on pathogenesis and clinical recommendations
Selva-O’Callaghan, A., Alvarado-Cárdenas, M., Pinal‐Fernandez, I., Araguás, E. T., Milisenda, J. C., Martínez, M. Á., Marín, A., Labrador‐Horrillo, M., Juárez, C., & Grau‐Junyent, J. M. (2018) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2018.1440206 · Cited by 206
Turner, R. M., & Pirmohamed, M. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm9010022 · Cited by 206
Side Effect Patterns in a Crossover Trial of Statin, Placebo, and No Treatment
Howard, J. P., Wood, F. A., Finegold, J. A., Nowbar, A. N., Thompson, D. M., Arnold, A. D., Rajkumar, C. A., Connolly, S., Cegla, J., Stride, C., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.07.022 · Cited by 198
Statin non-adherence and residual cardiovascular risk: There is need for substantial improvement
Banach, M., Stulc, T., Dent, R., & Toth, P. P. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.09.075 · Cited by 197
Ruscica, M., Ferri, N., Banach, M., Sirtori, C. R., & Corsini, A. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac020 · Cited by 218
Optimizing cholesterol treatment in patients with muscle complaints
Rosenson, R. S., Baker, S., Banach, M., Borow, K. M., Braun, L. T., Bruckert, E., Brunham, L. R., Catapano, A. L., Elam, M. B., Mancini, G. B. J., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.07.752 · Cited by 193
Self-citationNutraceutical therapies for atherosclerosis
Moss, J. W. E., & Ramji, D. P. (2016) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2016.103 · Cited by 193
Management of Statin Intolerance in 2018: Still More Questions Than Answers
Toth, P. P., Patti, A. M., Giglio, R. V., Nikolić, D., Castellino, G., Rizzo, M., & Banach, M. (2018) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-017-0259-7 · Cited by 193
Macedo, A. F., Taylor, F. C., Casas, J. P., Adler, A. J., Prieto‐Merino, D., & Ebrahim, S. B. J. (2014) · BMC Medicine · doi:10.1186/1741-7015-12-51 · Cited by 190
Cheeley, M. K., Saseen, J. J., Agarwala, A., Ravilla, S., Ciffone, N., Jacobson, T. A., Dixon, D. L., & Maki, K. C. (2022) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2022.05.068 · Cited by 197
Mancini, G. B. J., Tashakkor, A. Y., Baker, S., Bergeron, J., Fitchett, D., Frohlich, J., Genest, J., Gupta, M., Hegele, R. A., Ng, D. S., et al. (2013) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2013.09.023 · Cited by 173
Newman, C. B., Blaha, M. J., Boord, J. B., Cariou, B., Chait, A., Fein, H. G., Ginsberg, H. N., Goldberg, I. J., Murad, M. H., Subramanian, S., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa674 · Cited by 180
Statin-Associated Myopathy: Emphasis on Mechanisms and Targeted Therapy
Vinci, P., Panizon, E., Tosoni, L. M., Cerrato, C., Pellicori, F., Mearelli, F., Biasinutto, C., Fiotti, N., Girolamo, F. G. D., & Biolo, G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111687 · Cited by 188
Mora, J. C., & Valencia, W. M. (2018) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2017.08.007 · Cited by 196
Sex Differences in High-Intensity Statin Use Following Myocardial Infarction in the United States
Peters, S. A. E., Colantonio, L. D., Zhao, H., Bittner, V., Dai, Y., Farkouh, M. E., Monda, K. L., Safford, M. M., Muntner, P., & Woodward, M. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.02.032 · Cited by 173
Non-cardiovascular effects associated with statins
Desai, C. S., Martin, S. S., & Blumenthal, R. S. (2014) · BMJ · doi:10.1136/bmj.g3743 · Cited by 174
An assessment by the Statin Intolerance Panel: 2014 update
Guyton, J. R., Bays, H. E., Grundy, S. M., & Jacobson, T. A. (2014) · Journal of clinical lipidology · doi:10.1016/j.jacl.2014.03.002 · Cited by 165
Banach, M., Rizzo, M., Toth, P. P., Farnier, M., Davidson, M. H., Al-Rasadi, K., Aronow, W. S., Athyros, V., Djuric, D. M., Ezhov, M. V., et al. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.1039980 · Cited by 162
Moriarty, P. M., Jacobson, T. A., Bruckert, E., Thompson, P. D., Guyton, J. R., Baccara-Dinet, M. T., & Gipe, D. (2014) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2014.09.007 · Cited by 154
Self-citationPoly-ADP-ribosylation in health and disease
Bonicalzi, M.-È., Haince, J.-F., Droit, A., & Poirier, G. G. (2005) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-004-4505-1 · Cited by 157
Current and Emerging Uses of Statins in Clinical Therapeutics: A Review
Davies, J. T., Delfino, S., Feinberg, C. E., Johnson, M. F., Nappi, V. L., Olinger, J. T., Schwab, A., & Swanson, H. I. (2016) · Lipid Insights · doi:10.4137/lpi.s37450 · Cited by 156
Mechanisms of statin-associated skeletal muscle-associated symptoms
Bouitbir, J., Sanvee, G. M., Panajatovic, M. V., Singh, F., & Krähenbühl, S. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.03.010 · Cited by 152
The role of mitochondria in statin‐induced myopathy
Apostolopoulou, M., Corsini, A., & Roden, M. (2015) · European Journal of Clinical Investigation · doi:10.1111/eci.12461 · Cited by 142
Thompson, P. D., MacDougall, D. E., Newton, R. S., Margulies, J. R., Hanselman, J. C., Orloff, D. G., McKenney, J. M., & Ballantyne, C. M. (2016) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.12.025 · Cited by 142
Self-citationRosenson, R. S., Miller, K., Bayliss, M. S., Sanchez, R. J., Baccara‐Dinet, M. T., Chibedi-De-Roche, D., Taylor, B. A., Khan, I., Manvelian, G. Z., White, M. K., et al. (2017) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-017-6723-4 · Cited by 142
Statins and Musculoskeletal Conditions, Arthropathies, and Injuries
Mansi, I. A., Frei, C. R., Pugh, M. J., Makris, U. E., & Mortensen, E. M. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.6184 · Cited by 131
Cytokines: Roles in Atherosclerosis Disease Progression and Potential Therapeutic Targets
Moss, J. W. E., & Ramji, D. P. (2016) · Future Medicinal Chemistry · doi:10.4155/fmc-2016-0072 · Cited by 129
Li, P., Yin, Y., Guo, T., Sun, X., Ma, H., Zhu, M., Zhao, F., Xu, P. A., Chen, Y., Wan, G., et al. (2016) · Circulation · doi:10.1161/circulationaha.116.017949 · Cited by 126
Writing Committee Members, Blumenthal, R. S., Morris, P. B., Gaudino, M., Johnson, H. M., Anderson, T. S., Bittner, V. A., Blankstein, R., Brewer, L. C., Cho, L., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001423 · Cited by 122
Warden, B. A., Guyton, J. R., Kovacs, A. C., Durham, J. A., Jones, L. K., Dixon, D. L., Jacobson, T. A., & Duell, P. B. (2023) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2022.09.001 · Cited by 111
Ahmad, Z. (2014) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2014.02.033 · Cited by 110
Diagnosis and Management of Statin Intolerance
Rodrigo Alonso, K., Cuevas, A. M., & Cafferata, A. (2019) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv17030 · Cited by 110
Coming of Age: Considerations in the Prescription of Exercise for Older Adults
Zaleski, A. L., Taylor, B. A., Panza, G. A., Wu, Y., Pescatello, L. S., Thompson, P. D., & Fernández, A. B. (2016) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcj-12-2-98 · Cited by 107
Self-citationEssential amino acid supplementation in patients following total knee arthroplasty
Dreyer, H. C., Strycker, L. A., Senesac, H. A., Hocker, A. D., Smolkowski, K., Shah, S. N., & Jewett, B. A. (2013) · Journal of Clinical Investigation · doi:10.1172/jci70160 · Cited by 101
Statins, Muscle Disease and Mitochondria
Ramachandran, R., & Wierzbicki, A. S. (2017) · Journal of Clinical Medicine · doi:10.3390/jcm6080075 · Cited by 91
Unmet Needs in LDL-C Lowering: When Statins Won’t Do!
Krähenbühl, S., Pavik-Mezzour, I., & von Eckardstein, A. (2016) · Drugs · doi:10.1007/s40265-016-0613-0 · Cited by 89
NLA Task Force on Statin Safety - 2014 update
Jacobson, T. A. (2014) · Journal of clinical lipidology · doi:10.1016/j.jacl.2014.03.003 · Cited by 91
Statins and Physical Activity in Older Men
Lee, D. S. H., Markwardt, S., Goeres, L. M., Lee, C. G., Eckstrom, E., Williams, C. D., Fu, R., ORWOLL, E. S., Cawthon, P. M., Stefanick, M. L., et al. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.2266 · Cited by 90
Curing atherosclerosis should be the next major cardiovascular prevention goal
Robinson, J. G., & Gidding, S. S. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.04.009 · Cited by 87
Statin-associated muscle symptoms—Managing the highly intolerant
Backes, J. M., Ruisinger, J. F., Gibson, C., & Moriarty, P. M. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.01.006 · Cited by 88
Muscle- and skeletal-related side-effects of statins: tip of the iceberg?
Auer, J., Sinzinger, H. F., Franklin, B., & Berent, R. (2014) · European Journal of Preventive Cardiology · doi:10.1177/2047487314550804 · Cited by 88
Treatment Options for Statin-Associated Muscle Symptoms
Laufs, U., Scharnagl, H., Halle, M., Windler, E., Endres, M., & März, W. (2015) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2015.0748 · Cited by 85
Muntean, D. M., Thompson, P. D., Catapano, A. L., Stasiolek, M., Fabis, J., Muntner, P., Serban, M.-C., & Banach, M. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2016.09.001 · Cited by 82
Statin-Associated Muscle Disease: Advances in Diagnosis and Management
Taylor, B. A., & Thompson, P. D. (2018) · Neurotherapeutics · doi:10.1007/s13311-018-0670-z · Cited by 85
Self-citationPenson, P. E., Bruckert, É., MARAIS, D. P., Reiner, Ž., Pirro, M., Sahebkar, A., Bajraktari, G., Mirrakhimov, E. M., Rizzo, M., Mikhailidis, D. P., et al. (2022) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.12960 · Cited by 87
Statin Intolerance: A Literature Review and Management Strategies
Saxon, D. R., & Eckel, R. H. (2016) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2016.07.009 · Cited by 75
Brunham, L. R., Baker, S. K., Mammen, A. L., Mancini, G. B. J., & Rosenson, R. S. (2018) · Cardiovascular Research · doi:10.1093/cvr/cvy119 · Cited by 71
Statins for Primary Prevention in Older Adults—Moving Toward Evidence‐Based Decision‐Making
Singh, S., Zieman, S. J., Go, A. S., Fortmann, S. P., WENGER, N. K., Fleg, J. L., Radziszewska, B., Stone, N. J., Zoungas, S., & Gurwitz, J. H. (2018) · Journal of the American Geriatrics Society · doi:10.1111/jgs.15449 · Cited by 67
Muscle Toxicity of Drugs: When Drugs Turn Physiology into Pathophysiology
Janssen, L., Allard, N. A. E., Saris, C. G. J., Keijer, J., Hopman, M. T. E., & Timmers, S. (2019) · Physiological Reviews · doi:10.1152/physrev.00002.2019 · Cited by 71
Leblanc, A., Taylor, B. A., Thompson, P. D., Capizzi, J. A., Clarkson, P. M., White, C. M., & Pescatello, L. S. (2015) · SpringerPlus · doi:10.1186/s40064-015-1357-0 · Cited by 65
Self-citationPharmacogenomics for Primary Care: An Overview
Rollinson, V., Turner, R. M., & Pirmohamed, M. (2020) · Genes · doi:10.3390/genes11111337 · Cited by 64
An overview of statin-induced myopathy and perspectives for the future
Nikolić, D., Banach, M., Chianetta, R., Luzzu, L. M., Stoian, A. P., Diaconu, C. C., Citarrella, R., Montalto, G., & Rizzo, M. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1747431 · Cited by 65
Perera, R., McFadden, E. C., McLellan, J., Lung, T. W.-C., Clarke, P., Pérez, T., Fanshawe, T. R., Dalton, A., Farmer, A. A., Glasziou, P., et al. (2015) · Health Technology Assessment · doi:10.3310/hta191000 · Cited by 63
Lalwani, N. D., Hanselman, J. C., MacDougall, D. E., Sterling, L. R., & Cramer, C. T. (2019) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2019.05.003 · Cited by 72
Statins and Their Effect on PCSK9—Impact and Clinical Relevance
Taylor, B. A., & Thompson, P. D. (2016) · Current Atherosclerosis Reports · doi:10.1007/s11883-016-0604-3 · Cited by 65
Self-citationBeyond statins: New pharmacological targets to decrease LDL-cholesterol and cardiovascular events
Raschi, E., Casula, M., Cicero, A. F. G., Corsini, A., Borghi, C., & Catapano, A. L. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108507 · Cited by 67
Statin-Associated Myopathy: From Genetic Predisposition to Clinical Management
Vrablı́k, M., Zlatohlávek, L., Štulc, T., Adámková, V., Prusíková, M., Schwarzová, L., Hubacek, J. A., & Češka, R. (2014) · Physiological Research · doi:10.33549/physiolres.932865 · Cited by 59
Vaughan, R. A., Garcia-Smith, R., Bisoffi, M., Conn, C. A., & Trujillo, K. A. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.04.009 · Cited by 58
Statins Affect Skeletal Muscle Performance: Evidence for Disturbances in Energy Metabolism
Allard, N. A. E., Schirris, T. J. J., Verheggen, R. J. H. M., Rüssel, F. G. M., Rodenburg, R. J., Smeitink, J. A. M., Thompson, P. D., Hopman, M. T. E., & Timmers, S. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01561 · Cited by 59
Self-citationStatins, myalgia, and rhabdomyolysis
Tournadre, A. (2019) · Joint Bone Spine · doi:10.1016/j.jbspin.2019.01.018 · Cited by 59
Statin Intolerance: the Clinician’s Perspective
Štulc, T., Češka, R., & Gotto, A. M. (2015) · Current Atherosclerosis Reports · doi:10.1007/s11883-015-0552-3 · Cited by 59
The Potential of Isoprenoids in Adjuvant Cancer Therapy to Reduce Adverse Effects of Statins
Mo, H., Jeter, R., Bachmann, A., Yount, S. T., Shen, C., & Yeganehjoo, H. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01515 · Cited by 56
Muscle-related side-effects of statins
Taylor, B. A., & Thompson, P. D. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000174 · Cited by 53
Self-citationNguyen, T. N., Ngangue, P., Haggerty, J. L., Bouhali, T., & Fortin, M. (2019) · Family Practice · doi:10.1093/fampra/cmz023 · Cited by 52
Graham, J., Sanchez, R. J., Saseen, J. J., Mallya, U. G., Panaccio, M. P., & Evans, M. A. (2016) · Journal of clinical lipidology · doi:10.1016/j.jacl.2016.10.003 · Cited by 49
Statin Use and Knee Osteoarthritis Outcomes: A Longitudinal Cohort Study
Veronese, N., Koyanagi, A., Stubbs, B., Cooper, C. C., Guglielmi, G., Rizzoli, R., Schofield, P., Punzi, L., Al‐Daghri, N. M., Smith, L., et al. (2018) · Arthritis Care & Research · doi:10.1002/acr.23735 · Cited by 50
Expert opinion: the therapeutic challenges faced by statin intolerance
Patel, J., Martin, S. S., & Banach, M. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1197202 · Cited by 51
Mallinson, J. E., Marimuthu, K., Murton, A. J., Selby, A., Smith, K., Constantin‐Teodosiu, D., Rennie, M. J., & Greenhaff, P. L. (2015) · The Journal of Physiology · doi:10.1113/jphysiol.2014.285577 · Cited by 47
Drug‐related sarcopenia as a secondary sarcopenia
Kuzuya, M. (2023) · Geriatrics and gerontology international/Geriatrics & gerontology international · doi:10.1111/ggi.14770 · Cited by 46
Metadata
- Authors
- Parker, B. A., Capizzi, J. A., Grimaldi, A. S., Clarkson, P. M., Cole, S. M., Keadle, J., Chipkin, S., Pescatello, L. S., Simpson, K., White, C. M., & Thompson, P. D.
- Affiliations
- Hartford Hospital (US)
- Venue
- Circulation
- Published
- 2013-01
- Volume
- 127
- Issue
- 1
- Pages
- 96-103
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- PMC
- PMC4450764
- OpenAlex
- W1982914740
- Cited by
- 500
- References
- 27
- Citations by year
- 2026: 14 · 2025: 28 · 2024: 30 · 2023: 25 · 2022: 43 · 2021: 39 · 2020: 37 · 2019: 39 · 2018: 42 · 2017: 41 · 2016: 57 · 2015: 52 · 2014: 33 · 2013: 17
- FWCI
- 33.64
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Circulation (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Heart, Lung, and Blood Institute (R01HL081893)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Keywords
- statins, atorvastatin, skeletal muscle function, muscle strength, exercise capacity, creatine kinase, myalgia, statin-induced myopathy, high-intensity statin therapy, healthy volunteers
- MeSH terms
- Atorvastatin, Adult, Creatine Kinase, Double-Blind Method, Exercise Test, Female, Heptanoic Acids, Humans, Male, Middle Aged, Placebos, Pyrroles, Exercise Tolerance, Muscle, Skeletal, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Muscle Strength, Young Adult, Musculoskeletal Pain
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
